The COVID-19 crisis puts a spotlight on IP protection vs. public health

The pandemic has put the life sciences industry in the limelight globally in an unprecedented manner. On one hand there is a race to find COVID-19 diagnostics, treatments and vaccines which can be IP-protected, on the other hand is the public interest for equitable availability and affordability of essential drugs and treatments.

Our IP experts Sanna Wolk and Christopher Tehrani has together written an article for The Sweden BIO.

Read more here >>The COVID-19 crisis puts a spotlight on IP protection vs. public health